Published research has revealed that HPX has been linked to disease progression in pancreatic ductal adenocarcinoma (PDAC)—stromal HPX expression correlated with lymph node metastasis, suggesting that HPX may serve as a biomarker or potential therapeutic target in PDAC [40]—while fucosylated hemopexin showed significantly higher values in samples from patients with cirrhosis and HCC than hepatitis or normal individuals [41,42]. Here, HPX is linked to pancreatic ductal adenocarcinoma.